Page last updated: 2024-08-26

combretastatin and B16 Melanoma

combretastatin has been researched along with B16 Melanoma in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guchhait, SK; Kumari, A; Manne, RK; Panda, D; Santra, MK; Sisodiya, S; Srivastava, S1
Basso, G; Bortolozzi, R; Mitola, S; Porcù, E; Primac, I; Ravelli, C; Romagnoli, R; Ronca, R; Salvador, A; Vedaldi, D; Viola, G1
Haselwandter, CA; Kardar, M; Kohandel, M; Sengupta, S; Sivaloganathan, S1
Babu, B; Brockway, O; Dandavati, A; Lee, M; Mooberry, SL; Satam, V; Sjoholm, R; Tzou, S; Westbrook, C; Zeller, M1
Kiani, MF; Moore, BM; Nallamothu, R; Pattillo, CB; Sari-Sarraf, F; Wood, GC1
Capila, I; Eavarone, D; Kiziltepe, T; Sasisekharan, R; Sengupta, S; Watson, N; Zhao, G1

Other Studies

6 other study(ies) available for combretastatin and B16 Melanoma

ArticleYear
C12, a combretastatin-A4 analog, exerts anticancer activity by targeting microtubules.
    Biochemical pharmacology, 2019, Volume: 170

    Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Proliferation; Drug Delivery Systems; HeLa Cells; Humans; MCF-7 Cells; Melanoma, Experimental; Mice; Mice, Inbred NOD; Mice, SCID; Microtubules

2019
Vascular disrupting activity of combretastatin analogues.
    Vascular pharmacology, 2016, Volume: 83

    Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Antigens, CD; Bibenzyls; Cadherins; Capillary Permeability; Cardiac Myosins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Cells, Cultured; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Focal Adhesion Kinase 1; Human Umbilical Vein Endothelial Cells; Humans; Melanoma, Experimental; Mice, Inbred C57BL; Myosin Light Chains; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylation; Signal Transduction; Time Factors

2016
Quantitative model for efficient temporal targeting of tumor cells and neovasculature.
    Computational and mathematical methods in medicine, 2011, Volume: 2011

    Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Biological Availability; Carcinoma, Lewis Lung; Computer Simulation; Doxorubicin; Drug Delivery Systems; Drug Synergism; Liposomes; Melanoma, Experimental; Mice; Models, Biological; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Time Factors; Treatment Outcome

2011
A novel class of trans-methylpyrazoline analogs of combretastatins: synthesis and in-vitro biological testing.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Leukemia L1210; Melanoma, Experimental; Mice; Microtubules; Molecular Docking Simulation; Pyrazoles; Stilbenes; Structure-Activity Relationship; Tubulin Modulators

2011
Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay.
    Pharmaceutical research, 2005, Volume: 22, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Combined Modality Therapy; Drug Delivery Systems; Liposomes; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Stilbenes; Tumor Burden

2005
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.
    Nature, 2005, Jul-28, Volume: 436, Issue:7050

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Carcinoma, Lewis Lung; Coculture Techniques; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Endothelial Cells; Humans; Melanoma, Experimental; Mice; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Stilbenes; Time Factors; Tissue Distribution

2005